Finance

Beta
Lists
IMUX:NASDAQ
Immunic Inc
$15.65
+3.85%
(+0.58) 1D
Jun 26, 9:52:48 AM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for IMUX...
Open
$14.97
High
$15.77
Low
$14.93
Mkt. cap
213.18M
Avg. vol.
239.35K
Volume
9.53K
52-wk high
$15.77
52-wk low
$5.06
EPS
-$5.42
Beta
1.37
Shares outstanding
13.62M
No. of employees
95
Open
$14.97
High
$15.77
Low
$14.93
Mkt. cap
213.18M
Avg. vol.
239.35K
Volume
9.53K
52-wk high
$15.77
52-wk low
$5.06
EPS
-$5.42
Beta
1.37
Shares outstanding
13.62M
No. of employees
95
News stories
From sources across the web
About Immunic Inc
CEODaniel Vitt
Employees95
FoundedMay 2003
Headquarters-
SectorBiotechnology
Websiteimux.com
Analyst ratings
Based on 7 analysts giving stock ratings to IMUX in the past 3 months
Strong buy
Buy
6
Hold
1
Sell
0
12-month forecast
Based on 7 Wall Street analysts offering 12 month price targets for IMUX in the last 3 months.
Highest
Current $15.65
$56.00 (+257.83%)
Average
$29.80 (+90.42%)
Lowest
$19.00 (+21.41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
$22.00
+40.6%
06/08/2026
Paul Matteis
Stifel Nicolaus
Buy
Maintained
$25.00
+59.7%
05/28/2026
William Wood
B. Riley Securities
Buy
Maintained
$27.00
+72.5%
05/22/2026
Sam Slutsky
LifeSci Capital
Buy
Maintained
$56.00
+257.8%
05/16/2026
Boobalan Pachaiyappan
Roth MKM
Buy
Reiterated
$19.00
+21.4%
05/14/2026
Myles Minter
William Blair
Buy
Reiterated
-
-
05/13/2026
Jason Kolbert
D. Boral Capital
Hold
Downgraded
-
-
04/15/2026
Yatin Suneja
Guggenheim
Buy
Initiated
$70.00
+347.3%
03/24/2026
Last report
May 13, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.08 / -$0.96
-12.84%miss
Revenue / Est. (USD)
- / 0.00
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
-
-
-
-
Cost of goods sold
-
-
-
-
Cost of revenue
-
-
-
-
Research and development expenses
21.37M
20.01M
19.07M
25.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.71M
5.98M
4.26M
7.61M
Operating expense
27.08M
25.99M
23.33M
33.24M
Total operating expenses
27.08M
25.99M
23.33M
33.24M
Operating income
-27.08M
-25.99M
-23.33M
-33.24M
Other non operating income
22.00K
-5.00K
5.53M
-113.00K
EBT including unusual items
-26.82M
-25.58M
-19.30M
-32.59M
EBT excluding unusual items
-26.82M
-25.58M
-17.60M
-32.59M
Income tax expense
-
-
-
-
Effective tax rate
-
-
-
-
Other operating expenses
-
-
-
-
Net income
-26.82M
-25.58M
-19.30M
-32.59M
Net profit margin
-
-
-
-
Earnings per share
-2.00
-1.30
-0.70
-1.08
Interest and investment income
241.00K
419.00K
197.00K
760.00K
Interest expense
-
-
-
-
Net interest expenses
241.00K
419.00K
197.00K
760.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
-27.04M
-25.95M
-23.28M
-33.20M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of IMUX
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer